The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The Spinal Muscular Atrophy Treatment Market Over The Forecast Period?
The market size for spinal muscular atrophy treatments has experienced rapid expansion in recent years. It is projected to grow from $5.1 billion in 2025 to $5.89 billion in 2026, at a compound annual growth rate (CAGR) of 15.5%. Factors contributing to the market’s historical growth include limited therapeutic options for SMA, insufficient awareness of genetic disorders, a reliance on hospital-based treatment, slow adoption of innovative therapies, and a lack of early diagnosis programs.
The spinal muscular atrophy treatment market is projected to experience swift expansion over the coming years. It is anticipated to reach a size of $10.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.2%. This growth during the forecast period can be ascribed to several factors, including the emergence of advanced gene therapies, increased investment in SMA research, expanding newborn screening programs, the proliferation of specialized clinics and homecare services, and the incorporation of digital health and telemedicine technologies. Key trends anticipated within the same period encompass a greater uptake of gene therapy and SMN2 modifying treatments, an intensified emphasis on early diagnosis and newborn screening efforts, the expansion of homecare and specialty clinic-based SMA management approaches, the broadening of multidisciplinary care teams dedicated to SMA patients, and the seamless integration of telehealth and remote patient monitoring systems.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp
What Core Drivers Are Transforming The Spinal Muscular Atrophy Treatment Market?
The increasing attention on gene therapy is anticipated to drive the expansion of the spinal muscular atrophy treatment market in the future. Gene therapy is defined as a medical approach involving the alteration of an individual’s genetic material, specifically DNA or RNA, to address or prevent illnesses. This heightened emphasis on gene therapy largely stems from its capability to address or resolve the underlying cause of genetic conditions through direct modification or replacement of defective genes, thereby providing lasting or permanent therapeutic outcomes compared to conventional therapies. Spinal muscular atrophy treatments leverage gene therapy, exemplified by onasemnogene abeparvovec (Zolgensma), which offers a singular, targeted method to deliver a working copy of the SMN1 gene, substantially enhancing motor function and patient quality of life for those with SMA. As an illustration, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported a 10% rise in gene therapies undergoing Phase III trials during the fourth quarter of 2023 relative to the preceding quarter. This represented the first such increase witnessed since the third quarter of 2022. Consequently, the intensified focus on gene therapy is propelling the growth of the spinal muscular atrophy treatment market.
What Segment Types Are Included In The Spinal Muscular Atrophy Treatment Market Analysis?
The spinal muscular atrophy treatment market covered in this report is segmented –
1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments
2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications
2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises
3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy
4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy
Which Trends Are Guiding The Development Of The Spinal Muscular Atrophy Treatment Market?
Companies prominent in the spinal muscular atrophy treatment market are prioritizing the creation of novel formulations, including survival motor neuron 2 (SMN2) splicing modifier tablets, aimed at improving motor capabilities and decelerating disease progression. These SMN2 splicing modifier tablets are orally administered drugs formulated to modify the splicing of the SMN2 gene, thereby facilitating the generation of functional SMN protein, which is essential for the survival of motor neurons. By elevating the concentrations of full-length SMN protein, these tablets contribute to the treatment of spinal muscular atrophy (SMA), leading to enhanced muscle function and a reduction in the rate of disease progression. An example of this trend is Genentech, Inc., a US-based biotechnology company, which in February 2025 secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, notable as the inaugural and sole non-invasive SMN2 splicing modifier tablet indicated for SMA treatment. The Evrysdi tablet demonstrates similar effectiveness and safety profiles to existing oral solutions, while offering additional advantages like storage at room temperature and streamlined administration for patients 2 years and older weighing over 44 lbs (20 kgs), ultimately delivering increased convenience and adaptability in managing the condition.
Which Organizations Are Operating Within The Spinal Muscular Atrophy Treatment Market?
Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED
Access The Complete Spinal Muscular Atrophy Treatment Market Report:
Which Region Is The Primary Market For The Spinal Muscular Atrophy Treatment Market?
North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Spinal Muscular Atrophy Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp
Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Treatment Market 2026, By The Business Research Company
Spinal Surgery Devices And Equipment Market Report 2026
Cerebrospinal Fluid Management Csf Devices And Equipment Market Report 2026
Spinal Imaging Market Report 2026
https://www.thebusinessresearchcompany.com/report/spinal-imaging-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model